Cargando…
Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer
Antibodies targeting the receptor programmed death 1 on T cells have been approved for the treatment of lung cancer. Immune checkpoint inhibitors (ICIs) induce various immune-related adverse events. Life-threatening hematotoxicity can be provoked by ICI therapy. Although ICI-related endocrinopathy a...
Autores principales: | Mori, Hidenori, Sakai, Chizuru, Iwai, Masamichi, Sasaki, Yuka, Gomyo, Takenobu, Toyoshi, Sayaka, Kaito, Daizo, Yanase, Komei, Ito, Fumitaka, Endo, Junki, Funaguchi, Norihiko, Ohno, Yasushi, Minatoguchi, Shinya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557745/ https://www.ncbi.nlm.nih.gov/pubmed/31198679 http://dx.doi.org/10.1016/j.rmcr.2019.100871 |
Ejemplares similares
-
Primary Squamous Cell Lung Cancer With Frequent Episodes of Sustained Ventricular Tachycardia due to Myocardial Metastasis
por: Toyoshi, Sayaka, et al.
Publicado: (2023) -
Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer
por: Fujii, Hironori, et al.
Publicado: (2022) -
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial
por: Iihara, Hirotoshi, et al.
Publicado: (2019) -
Low‐Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin‐Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial
por: Sakai, Chizuru, et al.
Publicado: (2021) -
Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2020)